BIIB080
Sponsors
Biogen Idec Research Limited, Biogen
Conditions
Alzheimer's Disease DementiaHealthy VolunteerMild Cognitive Impairment Due to Alzheimer's DiseaseMild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disease Dementia
Phase 1
Phase 2
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Active, not recruitingNCT05399888
Start: 2022-08-24End: 2029-01-08Updated: 2025-05-18
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
WithdrawnCTIS2022-501644-15-00
Target: 327Updated: 2023-02-20
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
Active, not recruitingCTIS2022-501644-15-01
Start: 2023-09-28Target: 233Updated: 2025-10-24